Shares of The Cooper Cos. (NYSE:COO) gapped up before the market opened on Tuesday . The stock had previously closed at $183.92, but opened at $184.19. The Cooper Cos. shares last traded at $185.56, with a volume of 211,199 shares traded.

A number of brokerages have issued reports on COO. Robert W. Baird boosted their price target on shares of The Cooper Cos. from $185.00 to $196.00 and gave the stock an “outperform” rating in a research note on Thursday, August 18th. Zacks Investment Research lowered shares of The Cooper Cos. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $185.00 price target on shares of The Cooper Cos. in a research note on Tuesday, July 26th. JPMorgan Chase & Co. assumed coverage on shares of The Cooper Cos. in a research note on Wednesday, July 13th. They set a “buy” rating on the stock. Finally, Stifel Nicolaus upped their target price on shares of The Cooper Cos. from $180.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, June 30th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The Cooper Cos. presently has a consensus rating of “Buy” and an average price target of $168.10.

The firm’s 50 day moving average is $180.38 and its 200-day moving average is $161.33. The stock has a market capitalization of $9.00 billion and a price-to-earnings ratio of 43.95.

The Cooper Cos. (NYSE:COO) last released its quarterly earnings data on Thursday, June 2nd. The medical device company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.14. During the same quarter in the prior year, the company earned $1.72 earnings per share. The firm earned $484.80 million during the quarter. The Cooper Cos.’s quarterly revenue was up 11.5% on a year-over-year basis. On average, analysts predict that The Cooper Cos. will post $8.42 EPS for the current fiscal year.

The company also recently disclosed a semiannual dividend, which was paid on Friday, August 5th. Stockholders of record on Friday, July 22nd were paid a $0.03 dividend. This represents a dividend yield of 0.03%. The ex-dividend date was Wednesday, July 20th.

In related news, VP Randal Golden sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 28th. The stock was sold at an average price of $167.31, for a total transaction of $334,620.00. Following the transaction, the vice president now directly owns 2,044 shares of the company’s stock, valued at approximately $341,981.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael Kalkstein sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, July 8th. The stock was sold at an average price of $178.55, for a total value of $178,550.00. Following the transaction, the director now directly owns 14,215 shares in the company, valued at $2,538,088.25. The disclosure for this sale can be found here.

A number of institutional investors recently added to or reduced their stakes in the company. Schroder Investment Management Group raised its position in The Cooper Cos. by 13.1% in the fourth quarter. Schroder Investment Management Group now owns 307,100 shares of the medical device company’s stock valued at $41,213,000 after buying an additional 35,600 shares during the period. BlackRock Advisors LLC raised its position in The Cooper Cos. by 6.2% in the fourth quarter. BlackRock Advisors LLC now owns 577,463 shares of the medical device company’s stock valued at $77,495,000 after buying an additional 33,887 shares during the period. I.G. Investment Management LTD. raised its position in The Cooper Cos. by 40.6% in the fourth quarter. I.G. Investment Management LTD. now owns 30,760 shares of the medical device company’s stock valued at $4,128,000 after buying an additional 8,884 shares during the period. Principal Financial Group Inc. raised its position in The Cooper Cos. by 2.7% in the fourth quarter. Principal Financial Group Inc. now owns 154,051 shares of the medical device company’s stock valued at $20,674,000 after buying an additional 4,043 shares during the period. Finally, Andra AP fonden raised its position in The Cooper Cos. by 8.8% in the fourth quarter. Andra AP fonden now owns 9,900 shares of the medical device company’s stock valued at $1,329,000 after buying an additional 800 shares during the period.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.